BG Medicine (BG Medicine) Retained Earnings : $-166.31 Mil (As of Dec. 2015)

View and export this data going back to 2011. Start your Free Trial

What is BG Medicine Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BG Medicine's retained earnings for the quarter that ended in Dec. 2015 was $-166.31 Mil.

BG Medicine's quarterly retained earnings declined from Jun. 2015 ($-164.38 Mil) to Sep. 2015 ($-165.40 Mil) and declined from Sep. 2015 ($-165.40 Mil) to Dec. 2015 ($-166.31 Mil).

BG Medicine's annual retained earnings declined from Dec. 2013 ($-152.94 Mil) to Dec. 2014 ($-161.00 Mil) and declined from Dec. 2014 ($-161.00 Mil) to Dec. 2015 ($-166.31 Mil).

BG Medicine Retained Earnings Historical Data

The historical data trend for BG Medicine's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Retained Earnings Chart

BG Medicine Annual Data

Trend

Dec05

Dec06

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Retained Earnings

Get a 7-Day Free Trial

-113.32

-137.09

-152.94

-161.00

-166.31

BG Medicine Quarterly Data
	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15
Retained Earnings	Get a 7-Day Free Trial															-161.00	-162.35	-164.38	-165.40	-166.31

BG Medicine Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BG Medicine (OTCPK:BGMD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BG Medicine (BG Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 Wyman Street, Suite 300, Waltham, MA, USA, 02451

Website

http://www.bg-medicine.com

BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Executives

Jeffrey R Luber	director	100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox	director	ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp	10 percent owner	ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr	10 percent owner
Flagship Ventures Fund 2007, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel	director	320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r.	director	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines